Evidence map›Paper›PMID 36237334›Full record

ArticleFrontiers in oncology2022

Hematopoietic stem cell transplantation from HLA-matched sibling donors in children with acute lymphoblastic leukemia: A report from the Children's Cancer Hospital Egypt.

Mahmoud Hammad, Hanafy Hafez, Iman Sidhom, Dina Yassin, Sherine Salem, Khaled Alsheshtawi, Nayera Hamdy, Nahla Elsharkawy, Alaa Elhaddad

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mahmoud HammadPaediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Hanafy HafezPaediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Iman SidhomPaediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Dina YassinClinical Pathology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Sherine SalemClinical Pathology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Khaled AlsheshtawiClinical Research Department Children's Cancer Hospital Egypt, Cairo, Egypt.
Nayera HamdyClinical Pathology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Nahla ElsharkawyClinical Pathology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Alaa ElhaddadPaediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt, Cairo, Egypt.
Children Cancer Hospital · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Allogeneic hematopoietic stem cell transplantation (HSCT) is widely used for high-risk acute lymphoblastic leukemia (ALL) patients in their first complete remission (CR1), and for relapsed patients in second complete remission (CR2). Patients and methods: We retrospectively analyzed data for 67 children with ALL, from a cancer center in a low/middle income country, who had undergone HSCT from human leukocyte antigen (HLA)-matched sibling donors (MSDs) using myeloablative conditioning (MAC) regimens, between 2007 and 2020, describing the survival outcome and relapse probability after achieving CR1 and CR2 and determining outcome differences in relation to indications for HSCT in patients transplanted in CR1. All patients had achieved a negative minimal residual disease prior to transplant (<0.01%). Results: Forty-six patients (68.7%) were in CR1; 25 had adverse cytogenetics, including 18 patients with Philadelphia chromosome-positive ALL (Ph-positive ALL), and 21 had poor induction response. The 5-year overall survival (OS), event-free survival (EFS) and cumulative incidence of relapse (CIR) for the whole cohort were 56.1% (95% CI, 42.8%-69.4%), 49% (95% CI, 35.7%-62.3%) and 33.5% (95% CI, 21.7%-45.8%), respectively with better EFS and CIR for CR1 transplants compared to CR2 transplants (P=0.02 and P=0.03, respectively). Patients with Ph-positive ALL had better 5-year OS, EFS and non-relapse mortality (NRM) compared with other CR1 transplants (P=0.015, P=0.009 and P=0.028, respectively). Conclusion: Hematopoietic stem cell transplantation from MSD for ALL in CR1 group had superior outcomes compared to CR2 group and was apparently a curable option for Ph-positive ALL without an increased risk of non-relapse mortality. Poorer survival rates and higher relapse probabilities were associated with HSCT conducted to patients who had a poor response to induction therapy or suffered a relapse.

Indexed as

acute lymphoblastic leukemiahematopoietic stem cell transplantationlow and middle-income countriesmatched sibling donorpediatric

Identifiers

PMID36237334
PMCPMC9551213
OpenAlexW4297425287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.